Plain-English translation of NCT07422675 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called SER-252 (apomorphine) given as a single injection under the skin. Researchers want to understand how safe this medication is, how well patients tolerate it, and how the body processes it. The study will gradually test higher doses in small groups of people with Parkinson's disease who have trouble with "motor fluctuations"—times when their movement suddenly gets worse despite taking their regular medications.
People with advanced Parkinson's disease often struggle with unpredictable periods when their medications don't work well, leaving them "stuck" and unable to move smoothly. This study is testing whether the medication might offer a new treatment option for those difficult moments.
You likely qualify if…
You likely don't qualify if…
You will be part of one of five groups, with 8 participants per group. Most participants will receive a single subcutaneous injection (under the skin) of the medication delivered through a small device called enFuse, while a smaller group receives placebo (inactive substance). Your group will receive a specific dose level—each new group tests a slightly higher dose than the previous one. A few participants (sentinels) will be dosed first and carefully monitored before the rest of your group receives the injection. You'll need to return to the clinic for blood samples and health assessments on scheduled days so researchers can track how your body responds.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States
Australia